Choose Your Country or Region

mTOR

Isoform-selective Products

mTORC1 mTORC2

Signaling Pathway

mTOR Products

All (81)
mTOR Inhibitors (58)
mTOR Activators (4)
mTOR Modulators (3)
New mTOR Products

Catalog No.	Product Name	Information	Product Use Citations
S1039	Rapamycin	Rapamycin is a specific mTOR inhibitor with IC50 of ~0.1 nM in HEK293 cells.Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator and an immunosuppressant.	Nature, 2025, 10.1038/s41586-025-09018-7 Cell Metab, 2025, S1550-4131(25)00294-3 Cell Stem Cell, 2025, S1934-5909(25)00042-6
S1120	Everolimus	Everolimus is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.	Cancer Cell, 2025, 43(4):776-796.e14 Leukemia, 2025, 39(4):917-928 Cancer Res, 2025, 85(15):2805-2819
S1009	Dactolisib (BEZ235)	Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.	Nat Commun, 2025, 16(1):4502 Cell Rep Med, 2025, 6(1):101917 Cell Mol Biol Lett, 2025, 30(1):63
S1555	AZD8055	AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.	Signal Transduct Target Ther, 2025, 10(1):92 J Cereb Blood Flow Metab, 2025, 0271678X251321641 Commun Biol, 2025, 8(1):443
S2638	NU7441 (KU-57788)	NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.	Nat Cell Biol, 2025, 27(1):59-72 Nat Commun, 2025, 16(1):997 Nucleic Acids Res, 2025, 53(4)gkae1279
S2827	Torin 1	Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.	Cell Mol Immunol, 2025, NONE Nat Struct Mol Biol, 2025, 10.1038/s41594-025-01581-x Nat Commun, 2025, 16(1):1313
S1022	Ridaforolimus (Deforolimus, MK-8669)	Ridaforolimus (Deforolimus, MK-8669, AP23573) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. Phase 3.	JCI Insight, 2025, e186456 Front Oncol, 2025, 15:1486671 Nat Commun, 2024, 15(1):3636
S2811	Sapanisertib (MLN0128)	Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.	Mol Oncol, 2025, 19(1):151-172 Sci Adv, 2025, 11(6):eadq3802 Nat Aging, 2025, 5(7):1340-1357
S1038	PI-103	PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. PI-103 induces apoptosis in murine T-cell Lymphoma.	Nat Commun, 2025, 16(1):4828 Cell Rep, 2025, 44(5):115675 Anticancer Res, 2025, 45(5):1877-1896
S1044	Temsirolimus	Temsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.	Leukemia, 2025, 39(4):917-928 Cell Rep, 2025, 44(5):115617 JCI Insight, 2025, e186456
S2218	Torkinib (PP242)	Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively. Torkinib (PP242) induces mitophagy and apoptosis.	J Immunother Cancer, 2025, 13(3)e010753 Cell Rep, 2025, 44(4):115452 Int J Mol Sci, 2025, 26(16)7770
S2783	Vistusertib (AZD2014)	Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM. AZD2014 induces proliferation suppression, apoptosis, cell cycle arrest, and autophagy in HCC cells with antitumor activity.	NPJ Precis Oncol, 2025, 9(1):67 Sci Rep, 2025, 15(1):19445 Sci Rep, 2024, 14(1):25526
S7811	MHY1485	MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.	IBRO Neurosci Rep, 2025, 18:574-591 Bone Res, 2024, 12(1):15 J Exp Clin Cancer Res, 2024, 43(1):112
S1226	KU-0063794	KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.	JCI Insight, 2025, e186456 Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0 Nat Commun, 2024, 15(1):4083
S2817	Torin 2	Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively. Torin 2 decreases cell viability and induces autophagy and apoptosis.	J Gen Virol, 2025, 106(3)002086 Nat Commun, 2024, 15(1):7675 Microorganisms, 2024, 12(2)296
S2658	Omipalisib (GSK2126458)	Omipalisib (GSK2126458, GSK458) is a highly selective and potent inhibitor of p110α/β/δ/γ, mTORC1/2 with K_i of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM in cell-free assays, respectively. Omipalisib induces autophagy. Phase 1.	Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-24-0693 Int J Mol Sci, 2025, 26(16)7770 Cancers (Basel), 2025, 17(7)1152
S2743	PF-04691502	PF-04691502 (PF4691502) is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with K_i of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM in cell-free assays, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. PF-04691502 induces apoptosis. Phase 2.	Cell Death Discov, 2025, 11(1):266 Exp Gerontol, 2024, 186:112359 iScience, 2023, 26(9):107734
S2624	OSI-027	OSI-027 (ASP4786, CERC 006, AEVI-006) is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM in cell-free assays, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. OSI-027 induces autophagy in cancer cells.	Int J Mol Sci, 2025, 26(16)7770 Sci Rep, 2025, 15(1):19445 J Cell Commun Signal, 2023, 17(3):975-989
S2696	Apitolisib (GDC-0980)	Apitolisib (GDC-0980, RG7422, GNE 390) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. Also a mTOR inhibitor with K_i of 17 nM in a cell-free assay, and highly selective versus other PIKK family kinases. Apitolisib activates autophagy and apoptosis simultaneously in pancreatic cancer cells. Phase 2.	Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-24-0693 Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00939-5 Mol Oncol, 2024, 10.1002/1878-0261.13577
S2628	Gedatolisib (PKI-587)	Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.	PLoS One, 2025, 20(6):e0324443 bioRxiv, 2025, 2025.01.10.632413 Nat Commun, 2024, 15(1):686
S7369	4EGI-1	4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with K_D of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis.	Nat Commun, 2024, 15(1):4083 Nat Commun, 2024, 15(1):4083 Nucleic Acids Res, 2024, gkae849
S1360	GSK1059615	GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. Phase 1.	Am J Cancer Res, 2022, 12(3):1102-1115 BMC Cancer, 2020, 20(1):4 Cell Rep, 2019, 27(3):820-834
S1847	Clemastine fumarate	Clemastine fumarate is a selective histamine H1 receptor antagonist with IC50 of 3 nM. Clemastine stimulates autophagy via mTOR pathway.	Nat Commun, 2025, 16(1):1709 Nat Commun, 2025, 16(1):6382 Biomed Pharmacother, 2025, 185:117916
S1266	WYE-354	WYE-354 is a potent, specific and ATP-competitive inhibitor of mTOR with IC50 of 5 nM, blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) not P-AKT(T308), selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).	Cancers (Basel), 2020, 12(12)E3519 Oncol Rep, 2019, 41(6):3179-3188 Mol Ther Nucleic Acids, 2018, 11:485-493
S7646	Voxtalisib (XL765)	Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.	Toxicol Appl Pharmacol, 2022, 437:115886 Front Immunol, 2021, 12:761326 Biomed Res Int, 2021, 2021:6619730
S1627	Nitazoxanide	Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent(IC50 for canine influenza virus ranges from 0.17 to 0.21 μM). Nitazoxanide modulates autophagy and inhibits mTORC1 signaling.	iScience, 2025, 28(4):112218 Nat Commun, 2024, 15(1):8708 Mol Ther, 2024, S1525-0016(24)00340-X
S7891	CC-115	CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) with IC50 values of 0.013 μM and 0.021 μM, respectively. It has potential antineoplastic activity.	Nat Commun, 2024, 15(1):2625 Cells, 2024, 13(4)304 Mol Ther Nucleic Acids, 2023, 31:309-323
S2661	WYE-125132 (WYE-132)	WYE-125132 (WYE-132) is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.	Br J Haematol, 2022, 10.1111/bjh.18187 Cancers (Basel), 2022, 14(6)1575 Mol Cells, 2021, 44(1):50-62
S2749	BGT226 (NVP-BGT226) maleate	BGT226 (NVP-BGT226) maleate is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.	Cell Death Dis, 2025, 16(1):210 Cancers (Basel), 2024, 16(2)370 J Exp Clin Cancer Res, 2023, 42(1):99
S8317	3BDO	3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signaling pathway. It inhibits autophagy in HUVECs. 3BDO inhibits oxLDL-induced apoptosis.	NPJ Parkinsons Dis, 2024, 10(1):52 Adv Sci (Weinh), 2023, 10(13):e2205436 Research Square, 2023, 10.21203/rs.3.rs-3629594/v1
S2238	Palomid 529 (P529)	Palomid 529 (P529, SG 00529) inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3βS9, and pS6. Phase 1.	J Biomed Res, 2020, 0(0):1-9 Sci Rep, 2017, 7:41718 Mol Cancer Res, 2015, 13(2):223-30
S8322	Samotolisib (LY3023414)	Samotolisib (LY3023414, GTPL8918) is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.	Elife, 2025, 13RP95952 Mol Oncol, 2024, 10.1002/1878-0261.13703 Cancers (Basel), 2024, 16(20)3520
S1523	Voxtalisib (XL765) Analogue	Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.	Cell Oncol (Dordr), 2020, 8 Cell Rep, 2015, 11(3):446-59 Mol Cancer Res, 2014, 12(5):703-13
S8050	ETP-46464	ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.	mBio, 2024, e0228723. iScience, 2023, 25(7) Cell Rep, 2022, 41(11):111836
S2622	PP121	PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.	Life Sci Alliance, 2021, 4(2)e202000882 PLoS One, 2016, 11(10):e0164895 PLoS One, 2016, 11(10):e0164895
S3901	Astragaloside IV	Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2.	Cell Transplant, 2023, 32:9636897231198167 Cell Transplant, 2023, 32:9636897231198167 Cell Cycle, 2022, 1-14
S7091	Zotarolimus (ABT-578)	Zotarolimus (ABT-578,A 179578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.	Molecules, 2023, 28(6)2820 Molecules, 2023, 28(6), 2820 PLoS Biol, 2019, 17(5):e3000252
S8738	Bimiralisib (PQR309)	Bimiralisib (PQR309) is a novel brain-penetrant dual PI3K/mTOR inhibitor with in vitro and in vivo antilymphoma activity. It displays excellent selectivity versus PI3K-related lipid kinases, protein kinases and unrelated targets.	Cell Death Dis, 2024, 15(3):237 Haematologica, 2022, 10.3324/haematol.2021.279957 Cold Spring Harb Mol Case Stud, 2022, 8(1)a006140
S2396	Salidroside	Salidroside (Rhodioloside), a phenylpropanoid glycoside isolated from Rhodiola rosea, has been reported to have a broad spectrum of pharmacological properties. Salidroside is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.	PLoS One, 2024, 19(7):e0306926 Mol Med Rep, 2023, 27(2)37 Research Square, 2023, 10.21203/rs.3.rs-3696850/v1
S2689	WAY-600	WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).	Nat Commun, 2021, 12(1):2699 Front Cell Dev Biol, 2020, 8:383 Biochem Biophys Res Commun, 2016, 474(2):330-7
S8040	GDC-0349	GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR with K_i of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.	BMB Rep, 2021, 54(5):272-277 Cell Death Differ, 2020, 10.1038/s41418-020-00649-z Biochem Biophys Res Commun, 2016, 477(2):174-80
S8163	Paxalisib (GDC-0084)	Paxalisib (GDC-0084, RG7666) is a brain penetrant inhibitor of PI3K and mTOR with Kiapp values of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.	Cell Death Dis, 2025, 16(1):210 Cell Death Discov, 2023, 9(1):172 Cell Death Discov, 2023, 9(1):172
S8589	SF2523	SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.	Mol Ther Nucleic Acids, 2023, 31:309-323 Cell Biol Int, 2022, 10.1002/cbin.11833 Oncotarget, 2017, 8(58):98471-98481
S2406	Chrysophanic Acid	Chrysophanic Acid (Chrysophanol) a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor.	Int J Oncol, 2025, 66(3)20 Cell Prolif, 2020, e12871 Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8
S7886	Onatasertib (CC 223)	Onatasertib (CC 223) is a potent, selective, and orally bioavailable mTOR inhibitor with IC50 of 16 nM, >200-fold selectivity over the related PI3K-α. Phase 1/2.	Biochem Biophys Res Commun, 2018, 496(4):1191-1196 PLoS One, 2017, 12(3):e0173252
S2668	WYE-687	WYE-687 is an ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM; blocks mTORC1/pS6K(T389) and mTORC2/P-AKT(S473) but no effect observed on P-AKT(T308). Selectivity for mTOR is greater than PI3Kα (>100-fold) and PI3Kγ (>500-fold).	J Hepatol, 2015, 10.1016/j.jhep.2015.11.011
S7035	XL388	XL388 is a highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.	Autophagy, 2015, 11(10):1729-44
S6516	GNE-477	GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with an IC50 of 4 nM for PI3Kα and K_iapp of 21 nM for mTOR.	Front Pharmacol, 2021, 12:659511
S6517	GNE-493	GNE-493 (compound 5) is a potent, selective and orally available dual inhibitor of pan-PI3-kinase and mTOR with IC50 of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively.	Cell Death Discov, 2022, 8(1):120
F0169	mTOR Antibody [C15M14]		Nat Commun, 2025, 16(1):6668 Fertil Steril, 2020, 113(5):1067-1079.e5 Front Pharmacol, 2020, 11:128
F2584^New	Phospho-mTOR (Ser2448) Antibody [P18P17]	mTOR (phospho S2448),Phospho-mTOR (Ser2448),p-mTOR
F0339	Phospho-4E-BP1 (Ser65) Antibody [K8A20]	p-4E-BP1
F0358	Raptor Antibody [G12K8]
F2907^New	Phospho-P70 S6 Kinase β/SRK (Ser371) Antibody [A17F8]	P70 S6 Kinase beta/SRK (phospho S371)
F0663	TORC1/CRTC1 Antibody [F1J12]
F0691	LAMTOR1/C11orf59 Antibody [J20C8]		Biology (Basel), 2025, 14(5):477.
F1948	Phospho-Tuberin/TSC2 (Ser1387) Antibody [B6D9]
F2852^New	Raptor Antibody [H22E12]
F0842	LAMTOR2/ROBLD3 Antibody [F10G10]
F0606	RagA Antibody [B10P16]
F0239	PRAS40 Antibody [P22K6]
F1438	LAMTOR3/MAPKSP1 Antibody [L7A16]
E1151	JR-AB2-011	JR-AB2-011 is a potent inhibitor of mTOR-mLST8-mSIN1-Rictor complex (mTORC2) which can block mTORC2 signaling and Rictor association with mTOR at lower effective concentrations.	Int Immunopharmacol, 2025, 144:113681 Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0 iScience, 2024, 27(10):110939
S9514	Rotundic acid	Rotundic acid (Rutundic acid), a natural compound, exhibit cytotoxic activities toward human hepatocellular carcinoma (HepG2), malignant melanoma (A375), SCLC (NCI-H446), breast cancer (MCF-7), and colon cancer (HT-29) cell lines.RA induces cell cycle arrest, DNA damage, and apoptosis by modulating the AKT/mTOR and MAPK pathways.
S8267	RapaLink-1	RapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers.	Cell Chem Biol, 2025, 32(8):994-1012.e11
S5554	Lanatoside C	Lanatoside C is a cardiac glycoside with antiviral and anti-tumor activity. Lanatoside C induces G2/M cell cycle arrest and induces autophagy and apoptosis via attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways.
S6506	Compound 401	Compound 401 is a synthetic inhibitor of DNA-PK(IC50=0.28 μM) and mTOR (IC50=5.3 μM). It has no inhibition on p110α/p85α PI3K (>100 μM) and blocks the phosphorylation of S6 kinase 1 Thr389 and Akt Ser473 in COS7 cells.	Free Radic Biol Med, 2024, 224:831-845
E2375	PI3K/mTOR Inhibitor-2	PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with antitumor activity.
E2012	Ginkgolide K	Ginkgolide K, isolated from Ginkgo biloba, induces protective autophagy through the AMPK/mTOR/ULK1 signaling pathway, and possesses neuroprotective activity.
S8298	CZ415	CZ415, a potent ATP-competitive mTOR inhibitor with very good cell permeability.
F0533^New	Phospho-Rictor (Thr1135) Antibody [P16B3]
E0795	COH-SR4	COH-SR4 suppresses adipogenesis in 3T3-L1 cells through indirect activation of AMPK and downstream modulation of the Mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, which blocks important regulators involved in protein synthesis, cell cycle progression, and expression of key transcription factors and their target adipogenic genes involved in lipid synthesis.
S3753	L-Leucine	Leucine ((S)-Leucine, Leu) is one of nine essential amino acids in humans which is important for protein synthesis and many metabolic functions. It contributes to regulation of blood-sugar levels; growth and repair of muscle and bone tissue; growth hormone production; and wound healing. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
F2516^New	mTOR Antibody [L10A18]
S9736^New	ME-344	ME-344 is a synthetic metabolite of NV-128, a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, disrupting ATP generation and oxygen consumption. It also inhibits mTOR by downregulating the AKT/mTOR pathway, exhibiting anticancer activity by inhibiting cell growth and viability in leukemia cell lines with IC50 values of 70–260 nM.
E0115	MTI-31	MTI-31 (LXI-15029) is a novel mTORC1/mTORC2 inhibitor with Kd of 0.2 nM in mTOR binding assays and displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G.
S0179	mTOR inhibitor-1	mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy.
S9611	ABTL-0812	ABTL0812 (α-Hydroxylinoleic acid, LP-10218, SCLN-0812) inhibits Akt/mTOR axis by inducing the overexpression of TRIB3 and activating autophagy in lung squamous carcinoma cell lines. ABTL0812 also induces AMPK activation and ROS accumulation.
S8784	PQR620	PQR620 is a novel, selective, orally bioavailable and brain penetrant dual TORC1/2 inhibitor. PQR620 has anti-tumor activity across 56 lymphoma models with a median IC50 of 250 nM after 72 h of exposure.
E5815^New	YB-3-17	YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.
S7614	MHY-1685	MHY-1685 is a novel mTOR inhibitor, which attenuates senescence by modulating autophagy through the inhibition of mTOR in human cardiac stem cells.
S1039	Rapamycin	Rapamycin is a specific mTOR inhibitor with IC50 of ~0.1 nM in HEK293 cells.Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator and an immunosuppressant.	Nature, 2025, 10.1038/s41586-025-09018-7 Cell Metab, 2025, S1550-4131(25)00294-3 Cell Stem Cell, 2025, S1934-5909(25)00042-6
S1120	Everolimus	Everolimus is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.	Cancer Cell, 2025, 43(4):776-796.e14 Leukemia, 2025, 39(4):917-928 Cancer Res, 2025, 85(15):2805-2819
S1009	Dactolisib (BEZ235)	Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.	Nat Commun, 2025, 16(1):4502 Cell Rep Med, 2025, 6(1):101917 Cell Mol Biol Lett, 2025, 30(1):63
S1555	AZD8055	AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.	Signal Transduct Target Ther, 2025, 10(1):92 J Cereb Blood Flow Metab, 2025, 0271678X251321641 Commun Biol, 2025, 8(1):443
S2638	NU7441 (KU-57788)	NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.	Nat Cell Biol, 2025, 27(1):59-72 Nat Commun, 2025, 16(1):997 Nucleic Acids Res, 2025, 53(4)gkae1279
S2827	Torin 1	Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.	Cell Mol Immunol, 2025, NONE Nat Struct Mol Biol, 2025, 10.1038/s41594-025-01581-x Nat Commun, 2025, 16(1):1313
S1022	Ridaforolimus (Deforolimus, MK-8669)	Ridaforolimus (Deforolimus, MK-8669, AP23573) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. Phase 3.	JCI Insight, 2025, e186456 Front Oncol, 2025, 15:1486671 Nat Commun, 2024, 15(1):3636
S2811	Sapanisertib (MLN0128)	Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.	Mol Oncol, 2025, 19(1):151-172 Sci Adv, 2025, 11(6):eadq3802 Nat Aging, 2025, 5(7):1340-1357
S1038	PI-103	PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. PI-103 induces apoptosis in murine T-cell Lymphoma.	Nat Commun, 2025, 16(1):4828 Cell Rep, 2025, 44(5):115675 Anticancer Res, 2025, 45(5):1877-1896
S1044	Temsirolimus	Temsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.	Leukemia, 2025, 39(4):917-928 Cell Rep, 2025, 44(5):115617 JCI Insight, 2025, e186456
S2218	Torkinib (PP242)	Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively. Torkinib (PP242) induces mitophagy and apoptosis.	J Immunother Cancer, 2025, 13(3)e010753 Cell Rep, 2025, 44(4):115452 Int J Mol Sci, 2025, 26(16)7770
S2783	Vistusertib (AZD2014)	Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM. AZD2014 induces proliferation suppression, apoptosis, cell cycle arrest, and autophagy in HCC cells with antitumor activity.	NPJ Precis Oncol, 2025, 9(1):67 Sci Rep, 2025, 15(1):19445 Sci Rep, 2024, 14(1):25526
S1226	KU-0063794	KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.	JCI Insight, 2025, e186456 Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0 Nat Commun, 2024, 15(1):4083
S2817	Torin 2	Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively. Torin 2 decreases cell viability and induces autophagy and apoptosis.	J Gen Virol, 2025, 106(3)002086 Nat Commun, 2024, 15(1):7675 Microorganisms, 2024, 12(2)296
S2658	Omipalisib (GSK2126458)	Omipalisib (GSK2126458, GSK458) is a highly selective and potent inhibitor of p110α/β/δ/γ, mTORC1/2 with K_i of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM in cell-free assays, respectively. Omipalisib induces autophagy. Phase 1.	Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-24-0693 Int J Mol Sci, 2025, 26(16)7770 Cancers (Basel), 2025, 17(7)1152
S2743	PF-04691502	PF-04691502 (PF4691502) is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with K_i of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM in cell-free assays, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. PF-04691502 induces apoptosis. Phase 2.	Cell Death Discov, 2025, 11(1):266 Exp Gerontol, 2024, 186:112359 iScience, 2023, 26(9):107734
S2624	OSI-027	OSI-027 (ASP4786, CERC 006, AEVI-006) is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM in cell-free assays, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. OSI-027 induces autophagy in cancer cells.	Int J Mol Sci, 2025, 26(16)7770 Sci Rep, 2025, 15(1):19445 J Cell Commun Signal, 2023, 17(3):975-989
S2696	Apitolisib (GDC-0980)	Apitolisib (GDC-0980, RG7422, GNE 390) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. Also a mTOR inhibitor with K_i of 17 nM in a cell-free assay, and highly selective versus other PIKK family kinases. Apitolisib activates autophagy and apoptosis simultaneously in pancreatic cancer cells. Phase 2.	Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-24-0693 Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00939-5 Mol Oncol, 2024, 10.1002/1878-0261.13577
S2628	Gedatolisib (PKI-587)	Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.	PLoS One, 2025, 20(6):e0324443 bioRxiv, 2025, 2025.01.10.632413 Nat Commun, 2024, 15(1):686
S7369	4EGI-1	4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with K_D of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis.	Nat Commun, 2024, 15(1):4083 Nat Commun, 2024, 15(1):4083 Nucleic Acids Res, 2024, gkae849
S1360	GSK1059615	GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. Phase 1.	Am J Cancer Res, 2022, 12(3):1102-1115 BMC Cancer, 2020, 20(1):4 Cell Rep, 2019, 27(3):820-834
S1266	WYE-354	WYE-354 is a potent, specific and ATP-competitive inhibitor of mTOR with IC50 of 5 nM, blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) not P-AKT(T308), selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).	Cancers (Basel), 2020, 12(12)E3519 Oncol Rep, 2019, 41(6):3179-3188 Mol Ther Nucleic Acids, 2018, 11:485-493
S7646	Voxtalisib (XL765)	Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.	Toxicol Appl Pharmacol, 2022, 437:115886 Front Immunol, 2021, 12:761326 Biomed Res Int, 2021, 2021:6619730
S1627	Nitazoxanide	Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent(IC50 for canine influenza virus ranges from 0.17 to 0.21 μM). Nitazoxanide modulates autophagy and inhibits mTORC1 signaling.	iScience, 2025, 28(4):112218 Nat Commun, 2024, 15(1):8708 Mol Ther, 2024, S1525-0016(24)00340-X
S7891	CC-115	CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) with IC50 values of 0.013 μM and 0.021 μM, respectively. It has potential antineoplastic activity.	Nat Commun, 2024, 15(1):2625 Cells, 2024, 13(4)304 Mol Ther Nucleic Acids, 2023, 31:309-323
S2661	WYE-125132 (WYE-132)	WYE-125132 (WYE-132) is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.	Br J Haematol, 2022, 10.1111/bjh.18187 Cancers (Basel), 2022, 14(6)1575 Mol Cells, 2021, 44(1):50-62
S2749	BGT226 (NVP-BGT226) maleate	BGT226 (NVP-BGT226) maleate is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.	Cell Death Dis, 2025, 16(1):210 Cancers (Basel), 2024, 16(2)370 J Exp Clin Cancer Res, 2023, 42(1):99
S2238	Palomid 529 (P529)	Palomid 529 (P529, SG 00529) inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3βS9, and pS6. Phase 1.	J Biomed Res, 2020, 0(0):1-9 Sci Rep, 2017, 7:41718 Mol Cancer Res, 2015, 13(2):223-30
S8322	Samotolisib (LY3023414)	Samotolisib (LY3023414, GTPL8918) is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.	Elife, 2025, 13RP95952 Mol Oncol, 2024, 10.1002/1878-0261.13703 Cancers (Basel), 2024, 16(20)3520
S1523	Voxtalisib (XL765) Analogue	Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.	Cell Oncol (Dordr), 2020, 8 Cell Rep, 2015, 11(3):446-59 Mol Cancer Res, 2014, 12(5):703-13
S8050	ETP-46464	ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.	mBio, 2024, e0228723. iScience, 2023, 25(7) Cell Rep, 2022, 41(11):111836
S2622	PP121	PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.	Life Sci Alliance, 2021, 4(2)e202000882 PLoS One, 2016, 11(10):e0164895 PLoS One, 2016, 11(10):e0164895
S3901	Astragaloside IV	Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2.	Cell Transplant, 2023, 32:9636897231198167 Cell Transplant, 2023, 32:9636897231198167 Cell Cycle, 2022, 1-14
S7091	Zotarolimus (ABT-578)	Zotarolimus (ABT-578,A 179578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.	Molecules, 2023, 28(6)2820 Molecules, 2023, 28(6), 2820 PLoS Biol, 2019, 17(5):e3000252
S8738	Bimiralisib (PQR309)	Bimiralisib (PQR309) is a novel brain-penetrant dual PI3K/mTOR inhibitor with in vitro and in vivo antilymphoma activity. It displays excellent selectivity versus PI3K-related lipid kinases, protein kinases and unrelated targets.	Cell Death Dis, 2024, 15(3):237 Haematologica, 2022, 10.3324/haematol.2021.279957 Cold Spring Harb Mol Case Stud, 2022, 8(1)a006140
S2689	WAY-600	WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).	Nat Commun, 2021, 12(1):2699 Front Cell Dev Biol, 2020, 8:383 Biochem Biophys Res Commun, 2016, 474(2):330-7
S8040	GDC-0349	GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR with K_i of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.	BMB Rep, 2021, 54(5):272-277 Cell Death Differ, 2020, 10.1038/s41418-020-00649-z Biochem Biophys Res Commun, 2016, 477(2):174-80
S8163	Paxalisib (GDC-0084)	Paxalisib (GDC-0084, RG7666) is a brain penetrant inhibitor of PI3K and mTOR with Kiapp values of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.	Cell Death Dis, 2025, 16(1):210 Cell Death Discov, 2023, 9(1):172 Cell Death Discov, 2023, 9(1):172
S8589	SF2523	SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.	Mol Ther Nucleic Acids, 2023, 31:309-323 Cell Biol Int, 2022, 10.1002/cbin.11833 Oncotarget, 2017, 8(58):98471-98481
S2406	Chrysophanic Acid	Chrysophanic Acid (Chrysophanol) a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor.	Int J Oncol, 2025, 66(3)20 Cell Prolif, 2020, e12871 Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8
S7886	Onatasertib (CC 223)	Onatasertib (CC 223) is a potent, selective, and orally bioavailable mTOR inhibitor with IC50 of 16 nM, >200-fold selectivity over the related PI3K-α. Phase 1/2.	Biochem Biophys Res Commun, 2018, 496(4):1191-1196 PLoS One, 2017, 12(3):e0173252
S2668	WYE-687	WYE-687 is an ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM; blocks mTORC1/pS6K(T389) and mTORC2/P-AKT(S473) but no effect observed on P-AKT(T308). Selectivity for mTOR is greater than PI3Kα (>100-fold) and PI3Kγ (>500-fold).	J Hepatol, 2015, 10.1016/j.jhep.2015.11.011
S7035	XL388	XL388 is a highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.	Autophagy, 2015, 11(10):1729-44
S6516	GNE-477	GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with an IC50 of 4 nM for PI3Kα and K_iapp of 21 nM for mTOR.	Front Pharmacol, 2021, 12:659511
S6517	GNE-493	GNE-493 (compound 5) is a potent, selective and orally available dual inhibitor of pan-PI3-kinase and mTOR with IC50 of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively.	Cell Death Discov, 2022, 8(1):120
E1151	JR-AB2-011	JR-AB2-011 is a potent inhibitor of mTOR-mLST8-mSIN1-Rictor complex (mTORC2) which can block mTORC2 signaling and Rictor association with mTOR at lower effective concentrations.	Int Immunopharmacol, 2025, 144:113681 Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0 iScience, 2024, 27(10):110939
S8267	RapaLink-1	RapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers.	Cell Chem Biol, 2025, 32(8):994-1012.e11
S5554	Lanatoside C	Lanatoside C is a cardiac glycoside with antiviral and anti-tumor activity. Lanatoside C induces G2/M cell cycle arrest and induces autophagy and apoptosis via attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways.
S6506	Compound 401	Compound 401 is a synthetic inhibitor of DNA-PK(IC50=0.28 μM) and mTOR (IC50=5.3 μM). It has no inhibition on p110α/p85α PI3K (>100 μM) and blocks the phosphorylation of S6 kinase 1 Thr389 and Akt Ser473 in COS7 cells.	Free Radic Biol Med, 2024, 224:831-845
E2375	PI3K/mTOR Inhibitor-2	PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with antitumor activity.
S8298	CZ415	CZ415, a potent ATP-competitive mTOR inhibitor with very good cell permeability.
S9736^New	ME-344	ME-344 is a synthetic metabolite of NV-128, a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, disrupting ATP generation and oxygen consumption. It also inhibits mTOR by downregulating the AKT/mTOR pathway, exhibiting anticancer activity by inhibiting cell growth and viability in leukemia cell lines with IC50 values of 70–260 nM.
E0115	MTI-31	MTI-31 (LXI-15029) is a novel mTORC1/mTORC2 inhibitor with Kd of 0.2 nM in mTOR binding assays and displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G.
S0179	mTOR inhibitor-1	mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy.
S9611	ABTL-0812	ABTL0812 (α-Hydroxylinoleic acid, LP-10218, SCLN-0812) inhibits Akt/mTOR axis by inducing the overexpression of TRIB3 and activating autophagy in lung squamous carcinoma cell lines. ABTL0812 also induces AMPK activation and ROS accumulation.
S8784	PQR620	PQR620 is a novel, selective, orally bioavailable and brain penetrant dual TORC1/2 inhibitor. PQR620 has anti-tumor activity across 56 lymphoma models with a median IC50 of 250 nM after 72 h of exposure.
E5815^New	YB-3-17	YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.
S7614	MHY-1685	MHY-1685 is a novel mTOR inhibitor, which attenuates senescence by modulating autophagy through the inhibition of mTOR in human cardiac stem cells.
S7811	MHY1485	MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.	IBRO Neurosci Rep, 2025, 18:574-591 Bone Res, 2024, 12(1):15 J Exp Clin Cancer Res, 2024, 43(1):112
S8317	3BDO	3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signaling pathway. It inhibits autophagy in HUVECs. 3BDO inhibits oxLDL-induced apoptosis.	NPJ Parkinsons Dis, 2024, 10(1):52 Adv Sci (Weinh), 2023, 10(13):e2205436 Research Square, 2023, 10.21203/rs.3.rs-3629594/v1
S2396	Salidroside	Salidroside (Rhodioloside), a phenylpropanoid glycoside isolated from Rhodiola rosea, has been reported to have a broad spectrum of pharmacological properties. Salidroside is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.	PLoS One, 2024, 19(7):e0306926 Mol Med Rep, 2023, 27(2)37 Research Square, 2023, 10.21203/rs.3.rs-3696850/v1
S3753	L-Leucine	Leucine ((S)-Leucine, Leu) is one of nine essential amino acids in humans which is important for protein synthesis and many metabolic functions. It contributes to regulation of blood-sugar levels; growth and repair of muscle and bone tissue; growth hormone production; and wound healing. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
S1847	Clemastine fumarate	Clemastine fumarate is a selective histamine H1 receptor antagonist with IC50 of 3 nM. Clemastine stimulates autophagy via mTOR pathway.	Nat Commun, 2025, 16(1):1709 Nat Commun, 2025, 16(1):6382 Biomed Pharmacother, 2025, 185:117916
S9514	Rotundic acid	Rotundic acid (Rutundic acid), a natural compound, exhibit cytotoxic activities toward human hepatocellular carcinoma (HepG2), malignant melanoma (A375), SCLC (NCI-H446), breast cancer (MCF-7), and colon cancer (HT-29) cell lines.RA induces cell cycle arrest, DNA damage, and apoptosis by modulating the AKT/mTOR and MAPK pathways.
E0795	COH-SR4	COH-SR4 suppresses adipogenesis in 3T3-L1 cells through indirect activation of AMPK and downstream modulation of the Mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, which blocks important regulators involved in protein synthesis, cell cycle progression, and expression of key transcription factors and their target adipogenic genes involved in lipid synthesis.
F2584^New	Phospho-mTOR (Ser2448) Antibody [P18P17]	mTOR (phospho S2448),Phospho-mTOR (Ser2448),p-mTOR
F2907^New	Phospho-P70 S6 Kinase β/SRK (Ser371) Antibody [A17F8]	P70 S6 Kinase beta/SRK (phospho S371)
F2852^New	Raptor Antibody [H22E12]
F0533^New	Phospho-Rictor (Thr1135) Antibody [P16B3]
F2516^New	mTOR Antibody [L10A18]
S9736^New	ME-344	ME-344 is a synthetic metabolite of NV-128, a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, disrupting ATP generation and oxygen consumption. It also inhibits mTOR by downregulating the AKT/mTOR pathway, exhibiting anticancer activity by inhibiting cell growth and viability in leukemia cell lines with IC50 values of 70–260 nM.
E5815^New	YB-3-17	YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.

mTOR

Home PI3K/Akt/mTOR mTOR

Isoform-selective Products

Signaling Pathway

mTOR Products

Choose Selective mTOR Inhibitors